Can B Corp. subsidiary Nascent Pharma acquires two cannabis liquid formulation patents valued at $122M

Can B Corp

Nascent Pharma, 67% owned by Can B, acquired US patents 9,730,911 and 10,555,928 covering liquid cannabis formulations including beverages, tinctures, vape pens, and capsules.
Independent 2020 valuation set patent value at $122M, applying a 90% discount on projected income streams through August 2034.
Nascent agreed to pay prior patent owner's creditors 5% of Can B's share of Nascent revenues until aggregate $10M paid.
Consulting agreement with inventor entitles consultant to 50% of distributions Can B receives from Nascent.
Can B warns no assurance patents will generate revenue or achieve the $122M valuation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.